Blade Therapeutics Announced Its Acquisition of Atxco and Lead Anti-Fibrosis Candidate PAT-409
Senior Director of Multichannel Content for Pulmonary Fibrosis News, Michael Morale, discusses how Blade Therapeutics announced its acquisition of Atxco, and its lead anti-fibrosis candidate PAT-409.
Are you interested in learning more about Pulmonary Fibrosis? If so, please visit pulmonaryfibrosisnews.com/
What do you think about this news? Listen to this flash briefing episode and share your thoughts in the comment section below!
Sorry, there were no replies found.
Log in to reply.